REFERENCES
- Ripamonti C, Dyspnea Bruera B. Pathophysiology and assessment. J Pain Sympt Manage 1997; 13: 220–232
- Farncombe M, et al. The use of nebulized opioids for breathlessness. Palliative Medicine 1994; 8: 306–312
- Portenoy R K, Hagen N A. Breakthrough pain: Definition, prevalence and characteristics. Pain 1990; 41: 273–281
- Fine P G, Busch M. Characterization of breakthrough pains by hospice patients and their caregivers. J Pain Symptom Manage 1998; 16: 179–183
- Ashburn M A, Fine P G, Stanley T H. Oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain. Anesthesiology 1989; 71: 615–617
- Fine P G, Marcus M, DeBoer A J, Van der Oord B. An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 1991; 45: 149–153
- Simmonds M A. 1997, Oral transmucosal fentanyl citrate produces pain relief faster than medication typically used for breakthrough pain in cancer patients. American Society of Clinical Oncology (ASCO) Annual Meeting
- Lyss A P. 1997, Long-term use of oral transmucosal fentanyl citrate (OTFC) for breakthrough pain in cancer patients. American Society of Clinical Oncology (ASCO) Annual Meeting
- Coluzzi P. A titration study of oral transmucosal fentanyl citrate for breakthrough pain in cancer patients. American Society of Clinical Oncology (ASCO) Annual Meeting. 1997
- Cleary J F. Double-blind randomized study of the treatment of breakthrough pain in cancer patients: Oral transmucosal fentanyl citrate vs. placebo. American Society of Clinical Oncology (ASCO). 1997, Annual Meeting